Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Cryptogenic stroke

Full Text:


The paper considers the epidemiology and general etiological characteristics of cryptogenic stroke (CS). It discusses the concept of embolic stroke with an unknown source of embolism. It also characterizes the most significant causes of CS, such as paroxysmal atrial fibrillation, atrial cardiopathy, aortic atheroma, non-stenotic cerebral atherosclerotic plaques, and malignant neoplasms. The paper describes approaches to the diagnosis and secondary prevention of CS and proposes etiological and neuroimaging diagnostic algorithms for CI. Clinical cases are also presented.

About the Authors

A. A. Kulesh
Acad. E.A. Vagner Perm State Medical University, Ministry of Health of Russia; City Clinical Hospital Four
Russian Federation

26, Petropavlovskaya St., Perm 614990;

2, Kim St., Perm 614107

V. E. Drobakha
Acad. E.A. Vagner Perm State Medical University, Ministry of Health of Russia; City Clinical Hospital Four
Russian Federation

26, Petropavlovskaya St., Perm 614990;

2, Kim St., Perm 614107

V. V. Shestakov
Acad. E.A. Vagner Perm State Medical University, Ministry of Health of Russia
Russian Federation

26, Petropavlovskaya St., Perm 614990


1. Nouh A, Hussain M, Mehta T, Yaghi S. Embolic Strokes of Unknown Source and Cryptogenic Stroke: Implications in Clinical Practice. Front Neurol. 2016 Mar 21;7:37. doi: 10.3389/fneur.2016.00037. eCollection 2016.

2. Saver JL. Cryptogenic Stroke. N Engl J Med. 2016 May 26;374(21):2065-74. doi: 10.1056/NEJMcp1503946.

3. Kulesh AA, Drobakha VE,Shestakov VV. Sporadic cerebral non-amyloidmicroangiopathy: pathogenesis, diagnosis, and features of treatment policy. Nevrologiya,neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(4): 13-22. (In Russ.) doi: 10.14412/2074-2711-2018-4-13-22

4. Kulesh AA, Shestakov VV. Patent foramen ovale and embolic cryptogenic stroke. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(2):4-11. (In Russ.) doi: 10.14412/2074-2711-2019-2-4-11

5. Hart RG, Diener HC, Coutts SB, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014 Apr;13(4):429-38. doi: 10.1016/S1474-4422(13)70310-7.

6. Li L, Yiin GS, Geraghty OC, et al. Oxford Vascular Study. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. Lancet Neurol. 2015 Sep;14(9):903-913. doi: 10.1016/S1474-4422(15)00132-5. Epub 2015 Jul 27.

7. Ryoo S, Chung JW, Lee MJ, et al. An Approach to Working Up Cases of Embolic Stroke of Undetermined Source. J Am Heart Assoc. 2016 Mar 22;5(3):e002975. doi: 10.1161/JAHA.115.002975.

8. Kalashnikova LA, Dobrynina LA. Ischemic stroke at a young age. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017;117(8):3-12. (In Russ.)

9. Yaghi S, Bernstein RA, Passman R, Okin PM. Cryptogenic Stroke: Research and Practice. Circ Res. 2017 Feb 3;120(3):527-540. doi: 10.1161/CIRCRESAHA.116.308447.

10. Shamalov NA, Kustova MA. Cryptogenic stroke. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2014;6(2S):42-9. (In Russ.) doi: 10.14412/2074-2711-2014-2S-42-49

11. Hart RG, Catanese L, Perera KS, et al. Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update. Stroke. 2017 Apr;48(4):867-872. doi: 10.1161/STROKEAHA.116.016414. Epub 2017 Mar 6.

12. Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med. 2018 Jun 7;378(23):2191-2201. doi: 10.1056/NEJMoa1802686. Epub 2018 May 16.

13. Sposato LA, Cipriano LE, Saposnik G, et al.Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 2015 Apr; 14(4):377-87. doi: 10.1016/S1474-4422(15)70027-X. Epub 2015 Mar 4.

14. Albers GW, Bernstein RA, Brachmann J, et al. Heart Rhythm Monitoring Strategies for Cryptogenic Stroke: 2015 Diagnostics and Monitoring Stroke Focus Group Report. J Am Heart Assoc. 2016 Mar 15;5(3):e002944. doi: 10.1161/JAHA.115.002944.

15. Kirchhof P, Benussi S, Kotecha D, et al. ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct 7;37(38): 2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.

16. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2014 Jul;45(7):2160-236. doi: 10.1161/STR.0000000000000024. Epub 2014 May 1.

17. Haeusler KG, Grö schel K, Kö hrmann M, et al. Expert opinion paper on atrial fibrillation detection after ischemic stroke. Clin Res Cardiol. 2018 Oct;107(10):871-880. doi: 10.1007/s00392-018-1256-9. Epub 2018 Apr 27.

18. Bang OY, Ovbiagele B, Kim JS. Evaluation of cryptogenic stroke with advanced diagnostic techniques. Stroke. 2014 Apr;45(4):1186-94. doi: 10.1161/STROKEAHA.113.003720. Epub 2014 Feb 27.

19. Brambatti M, Connolly SJ, Gold MR, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014 May 27;129(21):2094-9. doi: 10.1161/CIRCULATIONAHA.113.007825. Epub 2014 Mar 14.

20. Elkind MSV. Atrial Cardiopathy and Stroke Prevention. Review. Curr Cardiol Rep. 2018 Sep 12;20(11):103. doi: 10.1007/s11886-018-1053-0.

21. Parfenov VA, Verbitskaya SV. The risk factors and prevention of stroke in atrial fibrillation. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2014;6(3):55-60. (In Russ.) doi: 10.14412/2074-2711-2014-3-55-60

22. Kamel H, Longstreth WT Jr, Tirschwell DL, et al. The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: Rationale and methods. Int J Stroke. 2019 Feb;14(2):207-214. doi: 10.1177/1747493018799981. Epub 2018 Sep 10.

23. Kong Q, Ma X. Contributing Mechanisms of Aortic Atheroma in Ischemic Cerebrovascular Disease. J Stroke Cerebrovasc Dis. 2015 Dec;24(12):2653-9. doi: 10.1016/j.jstrokecerebrovasdis.2015.09.033. Epub 2015 Oct 27.

24. Zavala JA, Amarrenco P, Davis SM, et al. Aortic arch atheroma. Int J Stroke. 2006 May;1(2):74-80. doi: 10.1111/j.1747-4949.2006.00026.x.

25. Cui X, Wu S, Zeng Q, et al. Detecting atheromatous plaques in the aortic arch or supra-aortic arteries for more accurate stroke subtype classification. Int J Neurosci. 2015 Feb;125(2):123-9. doi: 10.3109/00207454.2014.915825. Epub 2014 May 21.

26. Kim SW, Kim YD, Chang HJ, et al. Different infarction patterns in patients with aortic atheroma compared to those with cardioembolism or large artery atherosclerosis. J Neurol. 2018 Jan;265(1):151-158. doi: 10.1007/s00415-017-8685-7. Epub 2017 Nov 24.

27. Parfenov VA, Verbitskaya SV. Secondary prevention of ischemic stroke: international guidelines and clinical practice. Nevrologicheskii zhurnal. 2014;19(2):4-10. (InRuss.)

28. Amarenco P, Davis S, Jones EF, et al. Clopidogrel Plus Aspirin Versus Warfarin in Patients With Stroke and Aortic Arch Plaques. Stroke. 2014 May;45(5):1248-57. doi: 10.1161/STROKEAHA.113.004251. Epub 2014 Apr 3.

29. Ueno Y, Yamashiro K, Tanaka Y, et al. Rosuvastatin may stabilize atherosclerotic aortic plaque: transesophageal echocardiographic study in the EPISTEME trial. Atherosclerosis. 2015 Apr;239(2):476-82. doi: 10.1016/j.atherosclerosis.2015.02.021. Epub 2015 Feb 16.

30. Bulwa Z, Gupta A. Embolic stroke of undetermined source: The role of the nonstenotic carotid plaque. J Neurol Sci. 2017 Nov 15;382: 49-52. doi: 10.1016/j.jns.2017.09.027. Epub 2017 Sep 20.

31. Brinjikji W, Huston J3rd, Rabinstein AA, et al. Contemporary carotid imaging: from degree of stenosis to plaque vulnerability. J Neurol Sci. 2017 Nov 15;382:49-52. doi: 10.1016/j.jns.2017.09.027. Epub 2017 Sep 20.

32. Ritter MA, Dittrich R, Thoenissen N, et al. Prevalence and prognostic impact of microembolic signals in arterial sources of embolism. A systematic review of the literature. J Neurol. 2008 Jul;255(7):953-61. doi: 10.1007/s00415-008-0638-8. Epub 2008 May 6.

33. Migrino RQ, Bowers M, Harmann L, et al. Carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance: comparison with ultrasound intima media thickness. J Cardiovasc Magn Reson. 2011 Aug 3;13:37. doi: 10.1186/1532-429X-13-37.

34. DeMarco JK, Spence JD. Plaque Assessment in the Management of Patients with Asymptomatic Carotid Stenosis. Neuroimaging Clin N Am. 2016 Feb;26(1):111-27. doi: 10.1016/j.nic.2015.09.009. Epub 2015 Oct 17.

35. Navi BB, Iadecola C. Ischemic stroke in cancer patients: A review of an underappreciated pathology. Ann Neurol. 2018 May;83(5):873-883. doi: 10.1002/ana.25227. Epub 2018 Apr 30.

36. Navi BB, Reiner AS, Kamel H, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol. 2017 Aug 22;70(8): 926-938. doi: 10.1016/j.jacc.2017.06.047.

37. Kim SJ, Park JH, Lee MJ, et al. Clues to Occult Cancer in Patients with Ischemic Stroke. PLoS One. 2012;7(9):e44959. doi: 10.1371/journal.pone.0044959. Epub 2012 Sep 12.

38. Achiha T, Takagaki M, Oe H, et al. VoxelBased Lesion Mapping of Cryptogenic Stroke in Patient with Advanced Cancer: A Detailed Magnetic Resonance Imaging Analysis of Distribution Pattern. J Stroke Cerebrovasc Dis. 2017 Jul;26(7):1521-1527. doi: 10.1016/j.jstrokecerebrovasdis.2017.02.038. Epub 2017 Mar 28.

39. Parfenov VA. Prevention of venous thromboembolic events in ischemic stroke. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2013;5(3):49-54. (In Russ.) doi: 10.14412/2074-2711-2013-2341

40. Bushnell CD, Goldstein LB. Diagnostic testing for coagulopathies in patients with ischemic stroke. Stroke. 2000 Dec;31(12):3067-78.


For citations:

Kulesh A.A., Drobakha V.E., Shestakov V.V. Cryptogenic stroke. Neurology, Neuropsychiatry, Psychosomatics. 2019;11(4):14-21.

Views: 950

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)